Program
KAT6A/B Inhibitor BG-75202
Its studies are mostly in Breast Neoplasms, led by BeOne Medicines.
Furthest: phase 1, since Oct 28, 20252 company-led studies, 2 open or runningNext primary completion: Sep 30, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 22 open or running | phase 1since Oct 28, 2025 | Oct 28, 2025 | Sep 30, 2028phase 1 · NCT07619287 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 28, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07222267 · 186 planned · United States, Australia, China and more
- May 22, 2026Phase 1 study in Myeloid MalignancyNCT07619287 · 118 planned · Australia, China, New Zealand
Ahead
- Sep 30, 2028Primary completion: phase 1 study in Myeloid MalignancyNCT07619287
- Sep 30, 2029Primary completion: phase 1 study in Breast NeoplasmsNCT07222267
TargetBeta
“An orally bioavailable inhibitor of histone acetyltransferases KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| prifetrastat | Pfizer | phase 3 | 10 |
| HRS-2189 | Jiangsu HengRui Medicine | phase 1 | 2 |
| KAT6 Inhibitor OP-3136rule | olema-pharmaceuticals-inc | phase 1 | 1 |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 1 |
| KAT6/KAT7 Inhibitor IDE574rule | ideaya-biosciences | phase 1 | 1 |
| HLX97 | Fosun Pharma | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07619287Myeloid Malignancy · Australia, China, New Zealand | 1 | Recruiting | Sep 30, 2028 | 118 |
| NCT07222267Breast Neoplasms · United States, Australia, China and more | 1 | Recruiting | Sep 30, 2029 | 186 |
How it is read
Names in the registry
- “BG-75202”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.